

## Supplementary file 2: Supplementary Results

Belonging to the manuscript:

Cost-effectiveness of paediatric influenza vaccination in the Netherlands

Pieter T. de Boer<sup>1,\*</sup>, Franklin C.K. Dolk<sup>1\*</sup>, Lisa Nagy<sup>2,\*</sup>, Jan C. Wilschut<sup>3</sup>, Richard Pitman<sup>2</sup>, Maarten J. Postma<sup>1,3,4</sup>

<sup>1</sup> Unit of PharmacoTherapy, -Epidemiology & -Economics (PTE2), Department of Pharmacy, University of Groningen, Groningen, the Netherlands

<sup>2</sup> ICON Health Economics and Epidemiology, Oxfordshire, United Kingdom

<sup>3</sup> Department of Health Sciences, University Medical Center Groningen, Groningen, the Netherlands

<sup>4</sup> Department of Economics, Econometrics & Finance, Faculty of Economics & Business, University of Groningen, Groningen, the Netherlands

\*: These three authors have contributed equally to this manuscript

# 1. Results

## 1.1. Parameter output distributions

In the calibration initial parameter distributions were sampled, and those sets that met the fit criteria (I)-(IV) (Online Resource 1: Section 2.3) were kept. The exact number of parameter samples attempted was not recorded, but was estimated to be several million. Out of these parameter samples, 7,198 simulations were amassed which fit the heuristic criteria (I)-(IV). The resulting updated distributions are plotted in Figure S2.1 - Figure S2.7 and described in Table S2.1 – Table S2.3.

Sampling from uniform input distributions and keeping the samples that met the calibration criteria produced clearly defined, unimodal distributions (Figure S2.1) for the basic reproduction number (the number of secondary infections produced by an average primary infection in a totally susceptible population,  $R_0$ ); these distributions were clearly updated from their initial inputs by the acceptance-rejection sampling according to the calibration heuristic (Figure S2.2).




Figure S2.1: Distributions of basic reproductive number  $R_0$  parameter samples over the 7,198 runs of the calibrated model.




Figure S2.2: Distributions of basic reproductive number  $R_0$ : 7,198 samples without fit criteria applied (left), and the 7,198 runs of the calibrated model (right).

The input distributions for the durations of initial naturally-acquired immunity to influenza A viruses spanned a shorter range than the durations for influenza B (Online Resource 1: Table S1.8); this restriction is evident in the distributions for the calibrated model (Figure S2.3). In general, however, the output distributions for the durations of immunity, and for the probability of developing long-term immunity, did not have a mode that was much more defined than for their uninformed input distributions.




Figure S2.3: Distributions of duration of immunity parameter samples over the 7,198 runs of the calibrated model.

The pre-existing immunity scale factor sampling distribution for each virus had an upper bound due to the requirement that no age group be scaled to >100% immunity (Table S1.8). The upper bound for A (H3N2) is evident in the distribution of this scaling parameter for the calibrated model (Figure S2.4). For the other three viruses, the calibration resulted in unimodal distributions for the scale factor.




Figure S2.4: Distributions of pre-existing immunity scale parameter samples over the 7,198 runs of the calibrated model.

The updated parameter distributions for the seasonal forcing parameters were somewhat more defined than their uniform input distributions, with a slight tendency towards the middle of the sampling range (Online Resource 1: Table S1.8; Figure S2.5). The original, uniform, distribution for the seasonal forcing offset corresponded to peak transmissibility between late November and late January (Online Resource 1: Table S1.8).




Figure S2.5: Distributions of virus-independent parameter samples over the 7,198 runs of the calibrated model.

The number of new infectious cases seeded into monthly age bands each season did not have a strong influence on the model fit: its updated distribution remained near-uniform (Figure S2.5). The structural assumption of an annual “pulse” of seeding was chosen over continuous seeding for simplicity of implementation, with the expectation from earlier adaptations that the seeding mechanics would not greatly influence the model results, and so this result is both expected and reassuring.

The updated distribution for the probability of symptoms given influenza infection also did not change appreciably from its initial distribution (Figure S2.5; Table S2.1). This probability is the crucial link between (possibly asymptomatic) infection and symptomatic influenza infection. Structurally, however, it is merely applied to the incidence of all infection as output by the integration. It scales the results, not interacting directly with other parameters in the model structure; it is not unexpected, then, that the calibrated distribution is nearly unchanged from the input distribution.

Table S2.1: Transmission parameters sampled in the calibration and their output distributions.

<b>Input</b>	<b>All viruses</b>	<b>A H1N1</b>	<b>A H3N2</b>	<b>B Victoria</b>	<b>B Yamagata</b>
<b>Forcing parameters</b>					
Seasonal forcing magnitude	0.59 (0.22)	-	-	-	-
Annual seed amount per monthly age band	0.51 (0.28)	-	-	-	-
Seasonal forcing offset (days from Jan 1)	261 (16.97)	-	-	-	-
<b>R<sub>0</sub> parameters</b>					
Transmission coefficient	-	4.75 E-8 (1.53 E-8)	4.51 E-8 (1.47 E-8)	4.91 E-8 (1.57 E-8)	5.03 E-8 (1.56 E-8)
Latent period (days)	-	1.79 (0.80)	1.88 (0.79)	1.62 (0.85)	1.54 (0.85)
Infectious period (days)	-	1.68 (0.59)	2.49 (0.89)	1.93 (0.74)	2.37 (0.86)
R <sub>0</sub>	-	1.30 (0.21)	1.84 (0.36)	1.54 (0.28)	1.95 (0.37)
WAI FW matrix					
<b>Immunity parameters</b>					
Duration of initial naturally-acquired immunity (years)	-	6.22 (2.50)	5.21 (2.79)	18.11 (7.67)	13.46 (8.35)
Duration of long-term naturally-acquired immunity (years)	-	41.8 (17.0)	40.9 (17.3)	41.6 (17.3)	38.3 (17.5)
Probability of acquiring long-term immunity	-	0.53 (0.29)	0.53 (0.29)	0.50 (0.29)	0.50 (0.29)
Duration of vaccine-induced immunity (years)	-	1.81 (0.70)	1.69 (0.72)	1.78 (0.72)	1.84 (0.70)
Pre-existing immunity scaler	-	1.02 (0.49)	1.14 (0.30)	0.77 (0.30)	1.13 (0.24)
<b>Vaccination parameters</b>					
Vaccine efficacy					
Vaccination campaign duration (days)	35.1 (3.20)	-	-	-	-
<b>Probabilities</b>					
Probability of symptoms given infection	0.670 (0.042)	-	-	-	-

R<sub>0</sub>: Basic reproductive number, WAI FW: Who acquires infection from whom

Besides the probability of symptoms given influenza infection, almost all transmission inputs used uniform input distributions except the vaccine efficacy, which followed a lognormal distribution. The distributions for each virus are plotted in Figure S2.6 (inactivated) and Figure S2.7 (live-attenuated in sensitivity analysis). Although each virus was sampled separately, the updated vaccine efficacy distributions were visually nearly identical; averaged over all sampling age categories and all viruses, the output efficacy distributions were nearly unchanged from the input (Table S2.2 compared to Online Resource 1: Table S1.5).

Table S2.2: Efficacy values sampled during the model calibration and their output distributions.

<b>Age group</b>	<b>Main analysis IV and LAIV</b>		<b>Sensitivity analysis LAIV</b>	
	<b>Mean</b>	<b>95% CI</b>	<b>Mean</b>	<b>95% CI</b>
Children (0.5-<18)	47.4	(30.7, 60.9)	79.6	(69.7, 86.8)
Adults (18-<65)	58.8	(50.3, 66.2)	--	--
Elderly (≥65)	49.7	(39.1, 58.9)	--	--

IV: Inactivated vaccine, LAIV: Live-attenuated influenza vaccine




Figure S2.6: Distributions of inactivated vaccine efficacy samples over the 7,198 runs of the calibrated model.




Figure S2.7: Distributions of live-attenuated vaccine efficacy samples over the 7,198 runs of the calibrated model (used in sensitivity analysis).

For the WAIFW matrix all 225 entries were sampled independently. These entries did not show much overall change during the model calibration, as some were sampled larger than their means and others less, so the average

did not tend to vary. Of 225 entries, 78 changed by more than 2% between the sampling and output distributions, and of these 78, 8 had absolute changes of >0.10 contacts/day. For reference, in the original WAIFW matrix the average entry was 0.95 contacts/day. The majority of changes were due to entries with very small values, whose uniform sampling distribution was truncated at 0; the truncation shifted the average of this uniform distribution upwards.

The output probabilities of GP consultation given infection are provided in Table S2.3. These probabilities were calculated intrinsically during the model calibration as described in Online Resource 1: Section 3.2. These results may look somewhat counterintuitive in that the probability of GP consultation given infection in young children is quite low. The result is due to relatively low GP consultation rates in the input data [1], and high numbers of infections (possibly asymptomatic) output by the transmission model in this age group.

Table S2.3: Distributions (mean (SD)) of the probability of GP consultation given infection, calculated using the GP regression data[1] and modelled incidence, over the 7,198 runs of the calibrated model.

<b>Virus</b>	<b>0-&lt;5 years</b>	<b>5-&lt;20 years</b>	<b>20-&lt;60 years</b>	<b>60-&lt;100 years</b>
A H1N1	1.8% (0.8%)	4.4% (1.6%)	25.2% (10.4%)	33.1% (13.7%)
A H3N2	5.8% (2.8%)	6.0% (2.4%)	14.5% (7.1%)	33.3% (15.8%)
B Victoria	2.4% (1.9%)	2.1% (1.0%)	2.3% (1.8%)	7.3% (5.9%)
B Yamagata	3.5% (2.1%)	8.4% (2.9%)	6.6% (4.0%)	19.2% (12.3%)

## 1.2. Calibration fit results

The ranges of model output resulting from the acceptance-rejection approach over the calibration period is plotted in Figure S2.8-Figure S2.11. These figures were visually compared to the strain-specific GP consultation rates obtained from the regression [1], with their frequentist 95% confidence intervals.

The median and ranges of the transmission model generally overlap the confidence intervals of the regression. Generally the transmission model had difficulty fitting when there was a moderate epidemic one year and larger epidemic the next (e.g. Figure S2.9), or when the observed [1] variation between seasons was more varied in one age group than another (Figure S2.9, Figure S2.11).

The 2014/15 season demonstrates how quickly these sets of simulations can diverge from each other, despite strong agreement during the first four seasons. The boxplot height shows that the simulations produce a wide range of symptomatic infection rates. The boxplot whiskers represent the entire range of the plotted simulations, and this range widens in 2014/15 for all age groups for all four viruses.






Figure S2.8: Influenza A H1N1: comparison of GP consultation rates per 100,000 population obtained by the calibrated model (boxplot shows median and IQR) to those calculated by the regression model (mean and 95% CI).




Figure S2.9: Influenza A H3N2: comparison of GP consultation rates per 100,000 population obtained by the calibrated model (boxplot shows median and IQR) to those calculated by the regression model (mean and 95% CI).




Figure S2.10: Influenza B Victoria: comparison of GP consultation rates per 100,000 population obtained by the calibrated model (boxplot shows median and IQR) to those calculated by the regression model (mean and 95%CI).




Figure S2.11: Influenza B Yamagata: comparison of GP consultation rates per 100,000 population obtained by the calibrated model (boxplot shows median and IQR) to those calculated by the regression model (mean and 95%CI).

### 1.3. Expected net benefit

1 Table S2.4: 20-year average number of clinical outcomes per season in the Netherlands for all vaccination strategies explored.



#	Vaccination strategy Name	Symptomatic cases			GP visits			Hospitalizations			Deaths		
		Exp.	(95% range) <sup>a</sup>	Rate <sup>b</sup>	Exp.	(95% range) <sup>a</sup>	Rate <sup>b</sup>	Exp.	(95% range) <sup>a</sup>	Rate <sup>b</sup>	Exp.	(95% range) <sup>a</sup>	Rate <sup>b</sup>
1	No vaccination	1,157,285	(510,878-4,186,700)	6,755	172,603	(85,867-425,223)	1,007	2,560	(1073-7295)	14.94	523	(153-2377)	3.05
2	TIV	954,353	(462,235-2,960,578)	5,570	120,906	(71,688-212,412)	706	1,426	(700-2961)	8.32	274	(76-1152)	1.60
3	QIV	898,133	(445,978-2,848,591)	5,242	114,729	(68,743-201,573)	670	1,292	(638-2451)	7.54	213	(57-941)	1.24
4	TIV/TIV in 20% of 2-6y	911,514	(415,488-2,815,740)	5,320	114,633	(63,500-203,599)	669	1,363	(686-2910)	7.96	271	(72-1143)	1.58
5	TIV/TIV in 20% of 2-12y	850,715	(359,519-2,666,352)	4,965	104,992	(44,279-202,969)	613	1,265	(568-2944)	7.38	262	(71-1132)	1.53
6	TIV/TIV in 20% of 2-17y	832,783	(342,142-2,590,284)	4,861	102,108	(38,475-199,070)	596	1,234	(500-2884)	7.20	258	(63-1124)	1.51
7	TIV/TIV in 50% of 2-6y	853,115	(362,641-2,706,864)	4,979	106,125	(46,046-192,326)	619	1,274	(582-2730)	7.44	264	(74-1129)	1.54
8	TIV/TIV in 50% of 2-12y	734,350	(225,422-2,505,900)	4,286	86,626	(23,822-187,957)	506	1,086	(302-2767)	6.34	250	(60-1091)	1.46
9	TIV/TIV in 50% of 2-17y	691,051	(203,290-2,351,643)	4,033	79,320	(23,797-183,698)	463	1,006	(272-2721)	5.87	240	(56-1070)	1.40
10	TIV/TIV in 80% of 2-6y	811,996	(326,830-2,625,770)	4,739	100,238	(32,597-194,531)	585	1,214	(425-2830)	7.09	259	(63-1117)	1.51
11	TIV/TIV in 80% of 2-12y	667,106	(206,479-2,354,948)	3,894	75,996	(22,396-178,939)	444	983	(257-2685)	5.74	245	(51-1057)	1.43
12	TIV/TIV in 80% of 2-17y	609,581	(191,089-2,159,228)	3,558	66,319	(20,487-166,477)	387	875	(234-2514)	5.10	231	(48-1041)	1.35
13	TIV/Q-LAIV in 20% of 2-6y	893,504	(395,767-2,841,336)	5,215	113,162	(62,336-198,868)	660	1,340	(703-2504)	7.82	263	(72-1143)	1.54
14	TIV/Q-LAIV in 20% of 2-12y	802,143	(298,437-2,641,876)	4,682	100,992	(38,727-187,276)	589	1,210	(425-2796)	7.06	245	(62-1062)	1.43
15	TIV/Q-LAIV in 20% of 2-17y	775,457	(240,774-2,518,736)	4,526	97,415	(29,427-165,559)	569	1,171	(314-2314)	6.83	239	(56-1034)	1.39
16	TIV/Q-LAIV in 50% of 2-6y	817,610	(341,554-2,691,753)	4,772	103,417	(43,180-178,955)	604	1,235	(494-2412)	7.21	251	(61-1104)	1.47
17	TIV/Q-LAIV in 50% of 2-12y	619,176	(112,083-2,388,111)	3,614	76,943	(12,305-167,081)	449	952	(166-2586)	5.56	211	(27-903)	1.23
18	TIV/Q-LAIV in 50% of 2-17y	548,084	(74,821-2,200,169)	3,199	67,308	(7,856-134,861)	393	843	(108-1979)	4.92	191	(19-878)	1.12
19	TIV/Q-LAIV in 80% of 2-6y	764,723	(266,173-2,602,447)	4,463	96,702	(29,227-182,694)	564	1,162	(341-2752)	6.78	243	(51-1070)	1.42
20	TIV/Q-LAIV in 80% of 2-12y	506,794	(50,478-2,233,345)	2,958	62,507	(4,332-144,572)	365	795	(64-2278)	4.64	188	(11-863)	1.10
21	TIV/Q-LAIV in 80% of 2-17y	405,347	(19,240-1,885,841)	1,859	49,040	(1,342-130,300)	226	638	(19-2106)	2.84	158	(6-819)	0.67
22	QIV/Q-LAIV in 20% of 2-6y	838,230	(392,364-2,721,321)	4,892	107,096	(59,654-187,366)	625	1,210	(603-2291)	7.06	204	(56-920)	1.19
23	QIV/Q-LAIV in 20% of 2-12y	749,086	(270,384-2,532,340)	4,372	95,189	(34,890-164,250)	556	1,086	(390-2111)	6.34	188	(49-875)	1.10
24	QIV/Q-LAIV in 20% of 2-17y	723,473	(235,008-2,426,980)	4,223	91,708	(28,705-159,393)	535	1,048	(317-2021)	6.12	183	(46-868)	1.07
25	QIV/Q-LAIV in 50% of 2-6y	761,137	(309,280-2,567,393)	4,442	97,261	(39,245-168,471)	568	1,105	(444-2149)	6.45	193	(51-880)	1.12
26	QIV/Q-LAIV in 50% of 2-12y	565,024	(53,577-2,286,728)	3,298	71,267	(6,163-139,189)	416	835	(67-1792)	4.87	157	(11-841)	0.92
27	QIV/Q-LAIV in 50% of 2-17y	496,313	(26,593-2,075,552)	2,897	61,972	(3,188-126,244)	362	733	(35-1695)	4.28	141	(5-814)	0.82
28	QIV/Q-LAIV in 80% of 2-6y	707,717	(210,823-2,476,813)	4,131	90,572	(26,048-161,618)	529	1,034	(281-2057)	6.03	185	(39-866)	1.08

29	QIV/Q-LAIV in 80% of 2-12y	452,409	(7,994-2,108,728)	2,640	56,882	(1,019-120,068)	332	682	(10-1646)	3.98	137	(2-814)	0.80
30	QIV/Q-LAIV in 80% of 2-17y	354,037	(3,416-1,778,393)	2,066	43,805	(0,571-103,440)	256	535	(5-1557)	3.12	112	(1-759)	0.65
31	TIV/Q-LAIV+ in 20% of 2-6y	856,310	(369,333-2,753,662)	4,998	108,358	(56,987-195,118)	632	1,289	(642-2772)	7.52	258	(67-1114)	1.51
32	TIV/Q-LAIV+ in 20% of 2-12y	708,246	(195,895-2,556,890)	4,134	88,590	(23,486-176,818)	517	1,078	(290-2580)	6.29	229	(38-1041)	1.34
33	TIV/Q-LAIV+ in 20% of 2-17y	659,581	(152,617-2,429,955)	3,850	81,965	(19,598-169,493)	478	1,004	(257-2487)	5.86	216	(32-1009)	1.26
34	TIV/Q-LAIV+ in 50% of 2-6y	758,341	(254,892-2,610,007)	4,426	95,910	(31,009-170,615)	560	1,154	(377-2411)	6.73	243	(53-1075)	1.42
35	TIV/Q-LAIV+ in 50% of 2-12y	493,291	(46,261-2,254,275)	2,879	60,797	(4,143-146,573)	355	777	(62-2236)	4.54	186	(13-900)	1.08
36	TIV/Q-LAIV+ in 50% of 2-17y	387,888	(11,416-1,910,809)	2,264	46,800	(1,242-124,606)	273	613	(17-1937)	3.58	154	(3-816)	0.90
37	TIV/Q-LAIV+ in 80% of 2-6y	701,169	(185,868-2,542,311)	4,092	88,779	(21,135-172,567)	518	1,076	(261-2522)	6.28	234	(46-1040)	1.37
38	TIV/Q-LAIV+ in 80% of 2-12y	393,075	(18,221-2,019,129)	2,294	48,203	(1,337-123,858)	281	637	(19-1926)	3.72	164	(6-825)	0.96
39	TIV/Q-LAIV+ in 80% of 2-17y	264,510	(1,289-1,552,828)	1,544	31,208	(0,212-97,024)	182	431	(2-1579)	2.52	121	(0-705)	0.71
40	QIV/Q-LAIV+ in 20% of 2-6y	799,789	(345,478-2,630,448)	4,668	102,173	(53,695-177,506)	596	1,157	(606-2222)	6.75	198	(52-914)	1.16
41	QIV/Q-LAIV+ in 20% of 2-12y	653,698	(154,733-2,413,105)	3,815	82,775	(19,457-148,507)	483	956	(202-1922)	5.58	173	(29-857)	1.01
42	QIV/Q-LAIV+ in 20% of 2-17y	607,333	(122,701-2,286,500)	3,545	76,427	(15,051-140,165)	446	887	(158-1807)	5.18	162	(22-840)	0.95
43	QIV/Q-LAIV+ in 50% of 2-6y	701,151	(195,993-2,499,244)	4,092	89,772	(25,887-159,964)	524	1,025	(262-2042)	5.98	184	(37-863)	1.07
44	QIV/Q-LAIV+ in 50% of 2-12y	438,768	(6,855-2,121,998)	2,561	55,146	(0,978-115,979)	322	663	(10-1546)	3.87	134	(2-813)	0.78
45	QIV/Q-LAIV+ in 50% of 2-17y	336,423	(3,217-1,797,864)	1,964	41,553	(0,566-102,263)	243	510	(5-1481)	2.98	108	(1-747)	0.63
46	QIV/Q-LAIV+ in 80% of 2-6y	644,590	(117,128-2,392,510)	3,762	82,728	(14,442-153,274)	483	950	(148-1976)	5.55	176	(22-854)	1.03
47	QIV/Q-LAIV+ in 80% of 2-12y	338,260	(3,051-1,899,608)	1,974	42,538	(0,541-104,311)	248	525	(5-1434)	3.07	114	(1-770)	0.67
48	QIV/Q-LAIV+ in 80% of 2-17y	214,047	(0,806-1,442,495)	1,249	26,127	(0,145-81,588)	152	334	(1-1253)	1.95	78	(0-653)	0.46

---

2 GP: General practitioner, QIV: Quadrivalent inactivated vaccine, Q-LAIV: Quadrivalent live-attenuated influenza vaccine, Q-LAIV+: Q-LAIV with efficacy based on clinical trial data (higher  
3 efficacy as compared to the inactivated influenza vaccine), TIV: Trivalent inactivated vaccine, y: years of age. <sup>a</sup>:Exp: Expectation (average over 7,198 simulations) with range in which 95% of  
4 simulations fall. <sup>b</sup>: Rate per 100,000 person year.








Figure S2.12: 20-year average averted number of clinical events per year for different vaccination strategies as compared with the current programme with TIV. Clinical outcomes considered were: (A) symptomatic cases, (B) GP visits, (C) hospitalizations, and (D) deaths. Vaccination coverage in children in paediatric vaccination strategies was assumed at 50%. GP: General Practitioner, TIV: Trivalent Inactivated Vaccine, QIV: Quadrivalent Inactivated Vaccine, Q-LAIV: Quadrivalent Live-Attenuated Influenza Vaccine.

Table S2.5: Economic results of all considered strategies from a societal perspective summed up over a 20 year time-horizon. Results include an annual discount rate of 4% for costs and 1.5% for QALYs.

#	Strategy	Total QALY loss (thousands)	Total costs (€, millions)	NHB (thousands) <sup>a,b</sup>
1	No vaccination	125.41	6,687	-32.5
2	TIV	89.78	6,750	0.0
3	QIV	80.87	6,659	13.5
4	TIV/TIV in 20% of 2-6y	86.32	6,549	13.5
5	TIV/TIV in 20% of 2-12y	81.21	6,282	32.0
6	TIV/TIV in 20% of 2-17y	79.63	6,223	36.5
7	TIV/TIV in 50% of 2-6y	81.45	6,293	31.2
8	TIV/TIV in 50% of 2-12y	71.58	5,788	66.3
9	TIV/TIV in 50% of 2-17y	67.73	5,658	76.7
10	TIV/TIV in 80% of 2-6y	78.02	6,128	42.9
11	TIV/TIV in 80% of 2-12y	66.05	5,557	83.4
12	TIV/TIV in 80% of 2-17y	60.90	5,418	95.5
13	TIV/Q-LAIV in 20% of 2-6y	84.39	6,475	19.1
14	TIV/Q-LAIV in 20% of 2-12y	76.20	6,070	47.6
15	TIV/Q-LAIV in 20% of 2-17y	73.76	5,981	54.5
16	TIV/Q-LAIV in 50% of 2-6y	77.78	6,142	42.4
17	TIV/Q-LAIV in 50% of 2-12y	59.93	5,298	102.5
18	TIV/Q-LAIV in 50% of 2-17y	53.38	5,070	120.4
19	TIV/Q-LAIV in 80% of 2-6y	73.15	5,925	57.9
20	TIV/Q-LAIV in 80% of 2-12y	49.86	4,905	132.2
21	TIV/Q-LAIV in 80% of 2-17y	40.44	4,611	156.3
22	QIV/Q-LAIV in 20% of 2-6y	75.72	6,384	32.4
23	QIV/Q-LAIV in 20% of 2-12y	67.92	5,983	60.2
24	QIV/Q-LAIV in 20% of 2-17y	65.64	5,896	66.9
25	QIV/Q-LAIV in 50% of 2-6y	69.08	6,041	56.2
26	QIV/Q-LAIV in 50% of 2-12y	51.90	5,195	115.7
27	QIV/Q-LAIV in 50% of 2-17y	45.80	4,972	132.9
28	QIV/Q-LAIV in 80% of 2-6y	64.46	5,820	71.8
29	QIV/Q-LAIV in 80% of 2-12y	42.05	4,794	145.5
30	QIV/Q-LAIV in 80% of 2-17y	33.28	4,505	168.8
31	TIV/Q-LAIV+ in 20% of 2-6y	81.22	6,273	32.4
32	TIV/Q-LAIV+ in 20% of 2-12y	67.93	5,572	80.7
33	TIV/Q-LAIV+ in 20% of 2-17y	63.46	5,380	94.8
34	TIV/Q-LAIV+ in 50% of 2-6y	72.64	5,811	64.1
35	TIV/Q-LAIV+ in 50% of 2-12y	48.70	4,642	146.5
36	TIV/Q-LAIV+ in 50% of 2-17y	38.90	4,263	175.3
37	TIV/Q-LAIV+ in 80% of 2-6y	67.59	5,567	81.4
38	TIV/Q-LAIV+ in 80% of 2-12y	39.66	4,320	171.6
39	TIV/Q-LAIV+ in 80% of 2-17y	27.51	3,904	204.6
40	QIV/Q-LAIV+ in 20% of 2-6y	72.41	6,175	46.1
41	QIV/Q-LAIV+ in 20% of 2-12y	59.62	5,475	93.9
42	QIV/Q-LAIV+ in 20% of 2-17y	55.51	5,287	107.4
43	QIV/Q-LAIV+ in 50% of 2-6y	63.89	5,704	78.2
44	QIV/Q-LAIV+ in 50% of 2-12y	40.85	4,531	159.9
45	QIV/Q-LAIV+ in 50% of 2-17y	31.72	4,155	187.8
46	QIV/Q-LAIV+ in 80% of 2-6y	59.01	5,460	95.3
47	QIV/Q-LAIV+ in 80% of 2-12y	31.98	4,203	185.2
48	QIV/Q-LAIV+ in 80% of 2-17y	20.74	3,793	216.9

NHB: Net health benefit, QALY: Quality-adjusted life year, QIV: Quadrivalent inactivated influenza vaccine, Q-LAIV: Quadrivalent live-attenuated influenza vaccine, Q-LAIV+: Q-LAIV with efficacy based on clinical trial data (higher efficacy as

compared to the inactivated influenza vaccine), TIV: Trivalent inactivated influenza vaccine, y: years of age. <sup>a</sup>: As compared with TIV at current uptake rates. <sup>b</sup>: Calculated as:  $QALY - (Cost / \lambda)$ , with  $\lambda = €20,000/QALY$ ..

Table S2.6: Sensitivity analysis on the vaccination coverage in children aged 2-17 years. Cost-effectiveness results are summed up over a 20 year time-horizon. Results include an annual discount rate of 4% for costs and 1.5% for QALYs.

Policy	Total QALY loss (thousands)	Total costs (€, millions)	QALYs gained (thousands)	Incremental costs (€, millions)	ICER (€ per QALY gained)	NHB (thousands) <sup>a,c</sup>
TIV	89.78	6,750				
TIV/Q-LAIV 20% uptake	73.76	5,981			Dominated <sup>b</sup>	54.5
TIV/Q-LAIV 50% uptake	53.38	5,070			Dominated <sup>b</sup>	120.4
TIV/Q-LAIV 80% uptake	40.44	4,611	49.34	-2,139	Cost-saving	156.3

ICER: Incremental cost-effectiveness ratio, NHB: Net health benefit, QALY: Quality-adjusted life year, QIV: Quadrivalent inactivated influenza vaccine, Q-LAIV: Quadrivalent live-attenuated influenza vaccine, TIV: Trivalent inactivated vaccine, y: years of age. <sup>a</sup>: As compared with TIV at current uptake rates. <sup>b</sup>: Vaccination policies were listed as dominated when there was another policy with a QALY gain against lower costs (strict dominance) or a QALY gain against a lower ICER (extended dominance). <sup>c</sup>: NHB was calculated as:  $QALY - (Cost / \lambda)$ , with  $\lambda = €20,000/QALY$ .

Table S2.7: Outcomes of the probabilistic sensitivity analysis. Cost-effectiveness results are summed up over a 20 year time-horizon. Vaccination coverage in targeted children was assumed to be 50%. Results include an annual discount rate of 4% for costs and 1.5% for QALYs.

Policy	% of simulations resulting in a QALY gain and cost-savings	% of simulations resulting in a QALY gain and cost-effective for a threshold of €20,000 (excluding cost-savings)	% of simulations resulting in a QALY loss
TIV (compared with no vaccination)	52.9%	38.9%	0.0%
QIV (compared with TIV)	99.5%	0.4%	0.0%
TIV/TIV in 2–6y (compared with TIV)	97.7%	0.0%	2.3%
TIV/TIV in 2–12y (compared with TIV)	99.8%	0.0%	0.2%
TIV/TIV in 2–17y (compared with TIV)	99.9%	0.0%	0.1%
TIV/Q-LAIV in 2–17y (compared with TIV)	100.0%	0.0%	0.0%

QIV/Q-LAIV in 2–17y                      100.0%                      0.0%                      0.0%  
 (compared with TIV)

QALY: Quality-adjusted life year, QIV: Quadrivalent inactivated influenza vaccine, Q-LAIV: Quadrivalent live-attenuated influenza vaccine, TIV: Trivalent inactivated vaccine, y: years of age.

Table S2.8: Scenario analysis of paediatric influenza vaccination of 2-17 year-olds with quadrivalent live-attenuated influenza vaccine, while existing target-groups were vaccinated with trivalent inactivated vaccine. Results are compared to a strategy of vaccinating existing target-groups with trivalent inactivated vaccine. Results contain outcomes summed up over a time-horizon of 20 years.

Scenario	ΔQALYs (thousands)	ΔCosts (€, millions)	ICER <sup>a</sup> (€ per QALY gained)	NHB <sup>b</sup> (thousands)
Base case	36.4	-1,680	Dominant	120.4
<i>Costs</i>				
Q-LAIV price €3.59	36.4	-1,726	Dominant	122.7
Q-LAIV price €20.92	36.4	-1,328	Dominant	102.8
Healthcare payer's perspective	36.4	478	13,132	12.4
Human capital approach	36.4	-1,704	Dominant	121.6
No indirect HC costs	36.4	-1,847	Dominant	128.7
<i>Health effects</i>				
Halved LE of influenza premature death	32.2	-1,831	Dominant	123.8
Higher QALY loss per illness based on Lugner et al.[2]	71.9	-1,680	Dominant	155.7
<i>Coverage</i>				
20% uptake	16.0	-770	Dominant	54.5
80% uptake	49.3	-2,139	Dominant	156.3
<i>Vaccine efficacy</i>				
Q-LAIV efficacy based on RCT data	50.9	-2,487	Dominant	175.3
<i>Discount rate (per year)</i>				
Undiscounted	42.5	-2,196	Dominant	152.3
4% costs / 4% QALYs	29.0	-1,680	Dominant	113.0
1.5% costs / 1.5% QALYs	36.4	-1,977	Dominant	135.2

ICER: Incremental cost-effectiveness ratio, LE: Life-expectancy, NHB: Net health benefit, QALY: Quality-adjusted life year, Q-LAIV: Quadrivalent live-attenuated influenza vaccine. <sup>a</sup>: Scenarios were listed as dominant, when the scenario had lower QALY loss and lower costs as compared to current practice. <sup>b</sup>: Calculated as:  $\Delta\text{QALY} - (\Delta\text{Cost} * (1/\lambda))$ , with  $\lambda = €20,000/\text{QALY}$ .




Figure S2.13: Average impact of proposed influenza vaccination strategies on costs and QALY loss over a period of 20 years. Vaccination coverage in children in paediatric vaccination strategies was assumed at 50%. Future costs were annually discounted at 4% and QALY loss at 1.5%. GP: General Practitioner QIV: Quadrivalent inactivated vaccine, Q-LAIV: Quadrivalent live-attenuated influenza vaccine, TIV: Trivalent inactivated vaccine, y: years of age

Table S2.9: Economic outcomes stratified by component in the Netherlands for all vaccination strategies explored.

Strategy #	Name	Costs (€, millions)			Patients costs	Productivity losses	Total costs	QALY loss		Total
		Vaccination costs	Direct healthcare costs	Indirect healthcare costs				Illness	Premature mortality	
1	No vaccination	-	324	-	149	6,213	6,687	77.5	47.9	125.4
2	TIV	867	199	427	142	5,116	6,750	63.4	26.4	89.8
3	QIV	971	185	526	135	4,841	6,659	59.7	21.2	80.9
4	TIV/TIV in 20% of 2-6y	910	188	436	137	4,879	6,549	60.4	25.9	86.3
5	TIV/TIV in 20% of 2-12y	966	171	453	130	4,562	6,282	56.3	24.9	81.2
6	TIV/TIV in 20% of 2-17y	998	167	460	129	4,470	6,223	55.1	24.6	79.6
7	TIV/TIV in 50% of 2-6y	979	173	452	131	4,559	6,293	56.4	25.1	81.4
8	TIV/TIV in 50% of 2-12y	1,133	141	483	119	3,913	5,788	48.2	23.4	71.6
9	TIV/TIV in 50% of 2-17y	1,224	129	500	115	3,689	5,658	45.3	22.4	67.7
10	TIV/TIV in 80% of 2-6y	1,048	163	462	127	4,327	6,128	53.5	24.5	78.0
11	TIV/TIV in 80% of 2-12y	1,300	123	500	113	3,521	5,557	43.4	22.6	66.1
12	TIV/TIV in 80% of 2-17y	1,451	107	525	111	3,225	5,418	39.6	21.3	60.9
13	TIV/Q-LAIV in 20% of 2-6y	916	185	450	135	4,790	6,475	59.2	25.2	84.4
14	TIV/Q-LAIV in 20% of 2-12y	979	164	487	124	4,316	6,070	52.9	23.3	76.2
15	TIV/Q-LAIV in 20% of 2-17y	1,016	158	499	121	4,186	5,981	51.1	22.7	73.8
16	TIV/Q-LAIV in 50% of 2-6y	993	168	476	126	4,379	6,142	53.9	23.9	77.8
17	TIV/Q-LAIV in 50% of 2-12y	1,166	123	559	104	3,345	5,298	40.3	19.6	59.9
18	TIV/Q-LAIV in 50% of 2-17y	1,270	108	593	98	3,001	5,070	35.6	17.7	53.4
19	TIV/Q-LAIV in 80% of 2-6y	1,070	156	495	121	4,084	5,925	50.2	22.9	73.1
20	TIV/Q-LAIV in 80% of 2-12y	1,353	99	606	94	2,752	4,905	32.7	17.2	49.9
21	TIV/Q-LAIV in 80% of 2-17y	1,524	78	657	87	2,265	4,611	26.1	14.4	40.4
22	QIV/Q-LAIV in 20% of 2-6y	1,019	171	546	128	4,519	6,384	55.5	20.2	75.7
23	QIV/Q-LAIV in 20% of 2-12y	1,082	151	578	118	4,054	5,983	49.4	18.5	67.9
24	QIV/Q-LAIV in 20% of 2-17y	1,118	146	588	115	3,929	5,896	47.7	17.9	65.6
25	QIV/Q-LAIV in 50% of 2-6y	1,097	154	571	120	4,099	6,041	50.2	18.9	69.1
26	QIV/Q-LAIV in 50% of 2-12y	1,269	111	643	98	3,074	5,195	36.8	15.1	51.9
27	QIV/Q-LAIV in 50% of 2-17y	1,371	97	672	92	2,739	4,972	32.3	13.5	45.8
28	QIV/Q-LAIV in 80% of 2-6y	1,174	143	589	114	3,801	5,820	46.5	18.0	64.5
29	QIV/Q-LAIV in 80% of 2-12y	1,456	87	686	88	2,477	4,794	29.2	12.9	42.0
30	QIV/Q-LAIV in 80% of 2-17y	1,625	68	728	81	2,002	4,505	22.8	10.5	33.3
31	TIV/Q-LAIV+ in 20% of 2-6y	916	177	461	130	4,589	6,273	56.6	24.6	81.2
32	TIV/Q-LAIV+ in 20% of 2-12y	979	143	522	111	3,817	5,572	46.4	21.5	67.9
33	TIV/Q-LAIV+ in 20% of 2-17y	1,016	132	545	106	3,581	5,380	43.2	20.3	63.5
34	TIV/Q-LAIV+ in 50% of 2-6y	993	154	496	118	4,049	5,811	49.8	22.8	72.6
35	TIV/Q-LAIV+ in 50% of 2-12y	1,166	96	611	88	2,681	4,642	31.8	16.9	48.7
36	TIV/Q-LAIV+ in 50% of 2-17y	1,270	75	664	78	2,176	4,263	24.9	14.0	38.9
37	TIV/Q-LAIV+ in 80% of 2-6y	1,070	141	518	112	3,725	5,567	45.8	21.8	67.6
38	TIV/Q-LAIV+ in 80% of 2-12y	1,353	75	655	80	2,156	4,320	25.0	14.6	39.7
39	TIV/Q-LAIV+ in 80% of 2-17y	1,524	50	725	70	1,536	3,904	16.8	10.7	27.5
40	QIV/Q-LAIV+ in 20% of 2-6y	1,019	163	558	123	4,312	6,175	52.9	19.5	72.4
41	QIV/Q-LAIV+ in 20% of 2-12y	1,082	130	611	105	3,547	5,475	42.9	16.7	59.6
42	QIV/Q-LAIV+ in 20% of 2-17y	1,118	120	630	100	3,319	5,287	39.8	15.7	55.5
43	QIV/Q-LAIV+ in 50% of 2-6y	1,097	141	591	111	3,765	5,704	46.0	17.9	63.9



44	QIV/Q-LAIV+ in 50% of 2-12y	1,269	85	691	82	2,405	4,531	28.2	12.6	40.9
45	QIV/Q-LAIV+ in 50% of 2-17y	1,371	64	735	73	1,911	4,155	21.6	10.1	31.7
46	QIV/Q-LAIV+ in 80% of 2-6y	1,174	129	610	105	3,443	5,460	42.1	16.9	59.0
47	QIV/Q-LAIV+ in 80% of 2-12y	1,456	64	731	74	1,877	4,203	21.5	10.5	32.0
48	QIV/Q-LAIV+ in 80% of 2-17y	1,625	40	789	65	1,274	3,793	13.6	7.1	20.7

GP: General practitioner, QIV: Quadrivalent inactivated vaccine, Q-LAIV: Quadrivalent live-attenuated influenza vaccine, Q-LAIV+: Q-LAIV with efficacy based on clinical trial data (higher efficacy as compared to the inactivated influenza vaccine), TIV: Trivalent inactivated vaccine, y: years of age. <sup>a</sup>:Exp: Expectation (average over 7,198 simulations) with range in which 95% of simulations fall. <sup>b</sup>: Rate per 100,000 person year.

Table S2.11: 20-year cumulative economic outcomes when only the impact in children aged 2–17 years are considered. Vaccination coverage in children in paediatric vaccination strategies was assumed at 50%. Results include an annual discount rate of 4% for costs and 1.5% for QALYs.

Policy	Total QALYs (thousands)	Total costs (€, millions)	$\Delta$ QALY loss (thousands) <sup>a</sup>	$\Delta$ Costs (€, millions) <sup>a</sup>	ICER (€/QALY gained) <sup>b</sup>	NHB (thousands) <sup>a,c</sup>
No vaccination	26.95	692				-3.3
TIV	25.09	664	1.86	-28	Cost-saving	-
TIV/TIV in 2–6y	21.29	671			Dominated	3.5
TIV/Q-LAIV in 2–6y	20.09	649			Dominated	5.8
TIV/TIV in 2–12y	16.69	712			Dominated	6.0
TIV/TIV in 2–17y	15.43	779			Dominated	3.9
TIV/Q-LAIV in 2–12y	12.95	644	12.14	-20	Cost-saving	13.1
TIV/Q-LAIV in 2–17y	10.90	707	2.05	62	30,470	12.1

ICER: Incremental cost-effectiveness ratio, NHB: Net health benefit, QALY: Quality-adjusted life year, Q-LAIV: Quadrivalent live-attenuated influenza vaccine, TIV: Trivalent inactivated vaccine, y: years of age.

<sup>a</sup>: Compared with TIV for clinical risk groups at current uptake rates. <sup>b</sup>: Vaccination policies were listed as dominated when there was another policy with a QALY gain against lower costs (strict dominance) or a QALY gain against a lower ICER (extended dominance). <sup>c</sup>: Calculated as:  $\text{QALY} - (\text{Cost} / \lambda)$ , with  $\lambda = \text{€}20,000/\text{QALY}$ .

## 2. References

1. Dolk, F.C.K., De Boer, P.T., Nagy, L., Donker, G.A., Meijer, A., Postma, M.J., Pitman, R.: Consultations for influenza-like illness influenza-like illness in primary care in The Netherlands; a regression approach. (Submitted)
2. Lugner, A.K., Mylius, S.D., Wallinga, J.: Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. *Health Econ* **19**(5), 518-531 (2010). doi:10.1002/hec.1485